Direkt zum Inhalt
Merck
HomeWebinarsEmerging Applications of Silver Nanoparticles in Biotechnology

Emerging Applications of Silver Nanoparticles in Biotechnology



WEBINAR

Overview

Silver nanoparticles have extraordinary properties at the nanoscale, which are enabling a wave of innovative commercial products. Many of these new applications are in the field of bionanotechnology where the strong interaction between silver nanoparticles and specific wavelengths of light is utilized for applications such as sensing, imaging and therapeutics. This webinar discusses the properties of silver nanoparticles, the effect of the nanoparticle’s surface on the stability, dissolution, and transport of the nanoparticles in biological systems. Both the current and future biotechnology applications of silver nanoparticles have also been highlighted.

Areas Covered in the Webinar

  • Photothermal properties of silver nanoparticles
  • Silver nanoparticle selection in biotechnology
  • Stability, dissolution, and transport of the nanoparticles in biological systems
  • Current and future biotechnology applications of silver nanoparticles

Who Should Watch?

  • Materials Scientists
  • Biomedical Engineers
  • Chemical Engineers
  • Translational researcher

Speakers

Dr. Steven Oldenburg

Dr. Steven Oldenburg

nanoComposix, Inc.

CEO

Dr. Steve Oldenburg has over 20 years of nanotechnology experience beginning with his graduate work at Rice University where he discovered a method of fabricating gold nanoshells, a nanoscale composite material that consists of a spherical silica core surrounded by an ultra-thin shell of gold. This discovery led to the formation of Nanospectra Biosciences where the gold nanoshells are in clinical trials as a cancer therapy. After Rice, he joined Seashell Technology where he was responsible for identifying and developing commercial applications of nanotechnology, raising capital, and managing the scientific research team. In 2004, he founded nanoComposix to accelerate the commercialization of products based on precisely engineered and highly characterized nanoparticles. He is also a co-founder of Sienna Labs, a company that is developing therapies based on novel medical pigments. Steve has 6 issued patents and has over 30 nanotechnology publications that have received over 5000 citations.

Melden Sie sich an, um fortzufahren.

Um weiterzulesen, melden Sie sich bitte an oder erstellen ein Konto.

Sie haben kein Konto?